Abstract | BACKGROUND: OBJECTIVE: To determine the risk of GVHD in MSD HSCT for SCID patients compared to matched related donor (MRD). METHODS: This retrospective cohort study compares MSD with MRD and the outcome of GVHD in all SCID patients who underwent HSCT between 1993 and 2013. All statistical analyses were done using IBM SPSS statistics software. RESULTS: One hundred forty-five SCID patients underwent 152 HSCTs while 82 (54%) received GVHD prophylaxis. GVHD occurred in 48 patients (31.5%); 20/48 (42%) had GVHD prophylaxis compared to 28/48 (58%) that did not, P = 0.022. Acute GVHD occurred at a higher trend in MSD, 37/120 (30.8%), compared to MRD, 6/32 (18.8%), P = 0.17. We also analyzed the outcome according to the period of HSCT. The first period was 1993 to 2003, 48 HSCTs, 43 MSD, 5 MRD; all patients had GVHD prophylaxis, and there was no difference in GVHD. The second period was 2004 to 2013: of 104 HSCTs, 77 had MSD and 27 had MRD; GVHD prophylaxis was used in 22.1% of MSD and 63% of MRD, P = 0.000. GVHD was significantly higher in the MSD (40.2%) compared to MRD (18.5%) patients, P = 0.041. CONCLUSION: GVHD prophylaxis in MSD transplant should be considered in SCID patients.
|
Authors | Bandar Al-Saud, Alhanouf Al-Saleem, Bashayer Al Rasheed, Abdulaziz Al-Ghonaium, Ali Al-Ahmari, Hamoud Al-Mousa, Amal Al-Seraihy, Rand Arnaout, Abdullah Al-Jefri, Sahar Elshorbagi, Nazeema Elsayed, Hasan Al-Dhekri, Mouhab Ayas, Saleh Al-Muhsen |
Journal | Journal of clinical immunology
(J Clin Immunol)
Vol. 39
Issue 4
Pg. 414-420
(05 2019)
ISSN: 1573-2592 [Electronic] Netherlands |
PMID | 31041574
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Female
- Graft vs Host Disease
(diagnosis, etiology, prevention & control)
- HLA Antigens
(genetics, immunology)
- Hematopoietic Stem Cell Transplantation
(adverse effects, methods)
- Humans
- Infant
- Male
- Retrospective Studies
- Severe Combined Immunodeficiency
(complications, therapy)
- Siblings
- Treatment Outcome
|